If you take insulin or sulfonylureas: Discuss with your healthcare provider about potential dose adjustments, as reduced food intake may increase hypoglycemia risk
Gastrointestinal effects are among the most frequently reported adverse events with GLP-1 therapies and typically include nausea, vomiting, diarrhea, constipation, and abdominal pain
A 20mg/ml concentration means that every single milliliter of liquid in your vial contains 20 milligrams of tirzepatide
Managing blood glucose levels is crucial in diabetes care, lowering the risk of severe complications like kidney damage, eye issues, nerve damage, and limb loss
In plain terms, even if your body has developed some degree of resistance to GLP-1 signaling, the GIP pathway and the biased signaling properties of tirzepatide can still drive insulin response